The effect of astaxanthin in patients with poor ovarian response

The Effect of Astaxanthin on FMR1 Gene Expression in Human Granulosa Cells of Poor Ovarian Response Patients Who are Candidates for ART: Control by Methylation and Demethylation Mechanisms Mediated by TETs and DNMT3 Enzymes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250429065524N1

Enrollment

Registered

2025-05-13

Start date

2025-07-11

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor ovarian response. XV Pregnancy, childbirth and the puerperium

Interventions

Intervention 1: Control group: Placebo. Intervention 2: Intervention group: Astaxanthin.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Candidates for ICSI Previous poor response Abnormal ovarian reserve test

Exclusion criteria

Exclusion criteria: History of ovarian surgery History Endocrine or autoimmune disease History of male factor infertility Severe endometriosis Uterine and ovarian malformations Previous treatment with anti-oxidants History of using drugs affecting ovarian function

Design outcomes

Primary

Measure	Time frame
Antral Follicle Count. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Vaginal ultrasound.;TET enzyme gene. Timepoint: After the intervention is completed. Method of measurement: Real time PCR.;DNMT enzyme gene. Timepoint: After the intervention is completed. Method of measurement: Real time PCR.;FMR1 gene. Timepoint: After the intervention is completed. Method of measurement: Real time PCR.;FMR1 protein. Timepoint: After the intervention is completed. Method of measurement: Western Blot.;TET protein. Timepoint: After the intervention is completed. Method of measurement: Western Blot.;Number of oocytes retrieved. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Oocyte quality. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Number of high-quality embryos. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Fertilization rate. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Chemical pregnancy. Timepoint: After the intervention is completed. Method of measurement: Measurement of ß-HCG hormone in blood.;Clinical pregnancy. Timepoint: After the intervention is completed. Method of measurement: Ultrasound.;Body Mass Index (BMI). Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Wall scale and meter.;. Timepoint: . Method of measurement: .;Type of infertility. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Checklist.;Duration of infertility. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Checklist.;Group. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Checklist.;Malondialdehyde. Timepoint: After the intervention is completed. Method of measurement: ELISA.;Total Antio	—

Measure

Time frame

Antral Follicle Count. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Vaginal ultrasound.;TET enzyme gene. Timepoint: After the intervention is completed. Method of measurement: Real time PCR.;DNMT enzyme gene. Timepoint: After the intervention is completed. Method of measurement: Real time PCR.;FMR1 gene. Timepoint: After the intervention is completed. Method of measurement: Real time PCR.;FMR1 protein. Timepoint: After the intervention is completed. Method of measurement: Western Blot.;TET protein. Timepoint: After the intervention is completed. Method of measurement: Western Blot.;Number of oocytes retrieved. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Oocyte quality. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Number of high-quality embryos. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Fertilization rate. Timepoint: After the intervention is completed. Method of measurement: Optical microscope.;Chemical pregnancy. Timepoint: After the intervention is completed. Method of measurement: Measurement of ß-HCG hormone in blood.;Clinical pregnancy. Timepoint: After the intervention is completed. Method of measurement: Ultrasound.;Body Mass Index (BMI). Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Wall scale and meter.;. Timepoint: . Method of measurement: .;Type of infertility. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Checklist.;Duration of infertility. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Checklist.;Group. Timepoint: At the beginning of the study (before the intervention began). Method of measurement: Checklist.;Malondialdehyde. Timepoint: After the intervention is completed. Method of measurement: ELISA.;Total Antio

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMozhgan Fatahi Dehpahni

Tehran University of Medical Sciences

m-fatahid@razi.tums.ac.ir0098834290052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026